David Lassen shares insights on Prime/Magellan Rx analysis on GLP-1s for weight loss in new video - Prime Therapeutics
David Lassen shares insights on Prime/Magellan Rx analysis on GLP-1s for weight loss in new video
Following real-world analysis of GLP-1 drugs for weight loss, Prime/Magellan Rx releases new video about GLP-1 research
Earlier this year, Prime Therapeutics/Magellan Rx Management (Prime/MRx) announced a real-world analysis of glucagon-like peptide-1 agonist (GLP-1) drugs for weight loss, which found low adherence and increased cost among individuals taking the drug after one year.
WATCH: David Lassen, Chief Clinical Officer at Prime/MRx, shares additional insights on this study
As GLP-1 drugs continue to alter the health care landscape, Prime/MRx subject matter experts will continue keep the pulse on this dynamic trend with trusted data and insights. Check our news page for regular updates.
About Prime Therapeutics
Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization. We offer innovative pharmacy benefit management, specialty and medical drug management, and state government solutions to millions of people across the country. At Prime, we’re reimagining pharmacy solutions to provide the care we’d want for our loved ones. We challenge the way it’s always been done to develop intelligently designed solutions that deliver savings, simplicity and support to help people achieve better health. For more information, visit us at PrimeTherapeutics.com or follow us on LinkedIn.